Skip to main content

Advertisement

SpringerLink
Log in

Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients

  • Research Article
  • Published:
Tumor Biology

Abstract

The aim of this study was to evaluate the diagnostic and potential prognostic value of cell-free plasma DNA (CF-pDNA) in patients with suspected or histologically proven prostate cancer (PCa). We included 133 men with a diagnosis of PCa and 33 controls. PCa patients had blood samples prospectively drawn every 3 months for 2 years. CF-pDNA was measured by spectrophotometry. Considering a cut-off value of 140 ng/mL of CF-pDNA the area under the curve was of 0.824(0.757–0.879 with a sensitivity = 66.2 % and a specificity = 87.9 %) and the positive and negative likelihood ratio were of 5.46 and 0.39, respectively. CF-pDNA tends to decrease slightly and return to baseline values in about a week after biopsy. There was no statistical significant correlation between CF-pDNA levels at study entry with PSA, Gleason score, stage and biochemical recurrence free survival (BRFS). However, with a mean follow-up of 13.5 months, we could observe a significant shorter BRFS for patients with at least one value above 140 ng/mL of CF-pDNA during follow-up (p = 0.048). CF-pDNA is a potentially valuable biomarker for PCa diagnosis and a potential tool for the follow-up of patients with PCa.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. NIH/SEER database (2013) SEER Stat Fact Sheets: prostate. http://seer.cancer.gov/statfacts/html/prost.html#incidence-mortality. Accessed 29 Mar 2013.

  2. Serpa-Neto A, Tobias-Machado M, Wroclawski ML, Akerman M, Pompeo ACL, Del Giglio A. Descriptive study of prostate cancer mortality in the State of São Paulo, from 1980 to 2007. Einstein. 2010;8:433–6.

    Google Scholar 

  3. Wroclawski ML, Kuk C, Finelli A, Fleshner NE, Zlotta AR. Chemoprevention of prostate cancer: is there evidence from clinical trials? Clin Invest. 2011;1:1257–68.

    Article  CAS  Google Scholar 

  4. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59(1):61–71.

    Article  PubMed  Google Scholar 

  5. Guidelines On-line—SBU Nacional. Módulo 4—Urooncologia. http://sbu.org.br/pdf/guideline/4/CaProstata.pdf. Accessed 29 Jan 2013.

  6. Harvey P, Basuita A, Endersby D, Curtis B, Iacovidou A, Walker M. A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol. 2009;9:14.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Mosharafa AA, Torky MH, El Said WM, Meshref A. Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor. Urology. 2011;78:511–4.

    Article  PubMed  Google Scholar 

  8. Shapiro B, Chakrabarty M, Cohn EM, Leon SA. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer. 1983;51:2116–20.

    Article  CAS  PubMed  Google Scholar 

  9. Sozzi G, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res. 2001;61:4675–8.

    CAS  PubMed  Google Scholar 

  10. Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem. 2006;52:1062–9.

    Article  CAS  PubMed  Google Scholar 

  11. Trejo-Becerril C, Pérez-Cárdenas E, Treviño-Cuevas H, Taja-Chayeb L, García-López P, Segura-Pacheco B, et al. Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo, and clinical study on cervical cancer patients. Int J Cancer. 2003;104:663–8.

    Article  CAS  PubMed  Google Scholar 

  12. Chang HW, Lee SM, Goodman SN, Singer G, Cho SK, Sokoll LJ, et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst. 2002;94:1697–703.

    Article  CAS  PubMed  Google Scholar 

  13. Huang ZH, Li LH, Hua D. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett. 2006;243:64–70.

    Article  CAS  PubMed  Google Scholar 

  14. Ellinger J, Wittkamp V, Albers P, Perabo FG, Mueller SC, von Ruecker A, et al. Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. J Urol. 2009;181:363–71.

    Article  CAS  PubMed  Google Scholar 

  15. Ellinger J, Bastian PJ, Ellinger N, Kahl P, Perabo FG, Büttner R, et al. Apoptotic DNA fragments in serum of patients with muscle invasive bladder cancer: a prognostic entity. Cancer Lett. 2008;264:274–80.

    Article  CAS  PubMed  Google Scholar 

  16. Jung K, Stephan C, Lewandowski M, Klotzek S, Jung M, Kristiansen G, et al. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett. 2004;205:173–80.

    Article  CAS  PubMed  Google Scholar 

  17. Schwarzenbach H, Alix-Panabières C, Müller I, Letang N, Vendrell JP, Rebillard X, et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res. 2009;15:1032–8.

    Article  CAS  PubMed  Google Scholar 

  18. Chun FK, Müller I, Lange I, Friedrich MG, Erbersdobler A, Karakiewicz PI, et al. Circulating tumor-associated plasma DNA represents an independent and informative predictor of prostate cancer. BJU Int. 2006;98:544–8.

    Article  CAS  PubMed  Google Scholar 

  19. Serpa Neto A, Wroclavski ML, Pinto JLF, Marsicano SR, Delgado PO, Coelho PG, et al. Methodological standardization for the extraction of free DNA in plasma of peripheral blood. J Cancer Sci Ther. 2012. doi:10.4172/1948-5956.S5-005.

    Google Scholar 

  20. Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am. 2002;29:173–81.

    Article  PubMed  Google Scholar 

  21. Delgado PO, Alves BC, de Sousa GF, Kuniyoshi RK, Wroclavski ML, Del Giglio A, et al. Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumour Biol. 2013;34:983–6.

    Article  CAS  PubMed  Google Scholar 

  22. Levy DA, Jones JS. Management of rising prostate specific antigen after a negative biopsy. Curr Urol Rep. 2011;12:197–202.

    Article  PubMed  Google Scholar 

  23. Allen D, Butt A, Cahill D, Wheeler M, Popert R, Swaminathan R. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer. Ann NY Acad Sci. 2004;1022:76–80.

    Article  CAS  PubMed  Google Scholar 

  24. Papadopoulou E, Davilas E, Sotiriou V, Koliopanos A, Aggelakis F, Dardoufas K, et al. Cell-free DNA and RNA in plasma as a new molecular marker for prostate cancer. Oncol Res. 2004;14:439–45.

    CAS  PubMed  Google Scholar 

  25. Altimari A, Grigioni AD, Benedettini E, Gabusi E, Schiavina R, Martinelli A, et al. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am J Clin Pathol. 2008;129:756–62.

    Article  CAS  PubMed  Google Scholar 

  26. Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, et al. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy. Clin Cancer Res. 2007;13:5361–7.

    Article  CAS  PubMed  Google Scholar 

  27. Ellinger J, Bastian PJ, Haan KI, Heukamp LC, Buettner R, Fimmers R, et al. Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int J Cancer. 2008;122:138–43.

    Article  CAS  PubMed  Google Scholar 

  28. Boddy JL, Gal S, Malone PR, Harris AL, Wainscoat JS. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin Cancer Res. 2005;11:1394–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Albert Einstein Jewish Hospital, São Paulo, Brazil

    Marcelo L. Wroclawski & Auro del Giglio

  2. Department of Urology, ABC Medical School, Santo André, Brazil

    Marcelo L. Wroclawski, Ary Serpa-Neto, Oseas Castro-Neves-Neto, Alexandre S. F. L. Pompeo, Marcos T. Machado & Antonio C. L. Pompeo

  3. Department of Clinical Analysis, ABC Medical School, Santo André, Brazil

    Fernando L. A. Fonseca

  4. Department of Oncology, ABC Medical School, Santo André, Brazil

    Auro del Giglio

Authors
  1. Marcelo L. Wroclawski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ary Serpa-Neto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fernando L. A. Fonseca
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Oseas Castro-Neves-Neto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexandre S. F. L. Pompeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marcos T. Machado
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Antonio C. L. Pompeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Auro del Giglio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcelo L. Wroclawski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wroclawski, M.L., Serpa-Neto, A., Fonseca, F.L.A. et al. Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients. Tumor Biol. 34, 2921–2927 (2013). https://doi.org/10.1007/s13277-013-0854-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-0854-4

Keywords

Search

Navigation